Opinion|Videos|October 25, 2024
Long-Term Monitoring Protocols for Bispecific Therapy Complications
Panelists discuss how community practices implement protocols and processes to monitor and manage potential long-term complications or adverse events associated with bispecific therapy, focusing on patient follow-up, adverse event reporting, and ongoing risk assessment.
Advertisement
Episodes in this series
- What protocols and processes do you have in place at the community practice to continue monitoring and managing potential long-term complications or adverse events associated with bispecific therapy?
Advertisement
Related to this article
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Advertisement
Advertisement
Trending on CancerNetwork
1
Acting on a HER2 Result and Navigating Access to Therapy
2
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
3
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
4
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
5